Non-Hodgkin Lymphoma
News
FDA approves new use for ibrutinib in WM
The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica®) for use in combination with rituximab to treat adults with...
News
Combo produces high response rate in CLL
Bendamustine followed by obinutuzumab and venetoclax produces a high overall response rate in chronic lymphocytic leukemia (CLL), according to...
News
Signal strength tied to potency of CAR T-cell therapy
Investigators found that chimeric antigen receptor (CAR) T cells with stronger signaling capabilities were less effective against lymphoma cells...
News
Role of SES in childhood cancer survival disparities
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed...
News
Access to care drives disparity between urban, rural cancer patients
New research suggests that better access to quality care may reduce disparities in survival between cancer patients living in rural areas of the...
News
CPI-613 receives orphan designation for PTCL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma (PTCL)....
News
Real-world bleeding risk with ibrutinib
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking...
News
Mogamulizumab prolongs PFS in CTCL
Mogamulizumab is an effective treatment option for relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to researchers. In the phase 3...
News
Auto-HSCT linked to higher AML, MDS risk
Patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) for lymphoma or myeloma have an increased risk of acute myeloid...
News
Group releases new CLL guidelines
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do...
News
Insurance status linked to survival in FL patients
Having health insurance can mean the difference between life and death for US patients with follicular lymphoma (FL), according to research...